Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use ADEMPAS safely and effectively. See full prescribing information for ADEMPAS.ADEMPAS (riociguat) tablets, for oral useInitial U.S. Approval: 2013
Medication labelWhy this: Advisory · dailymed-prescription
Adempas is indicated for the treatment of adults with persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH), (WHO Group 4) after surgical treatment, or inoperable CTEPH, to improve exercise capacity and WHO functional class [see Clinical Studies (14.1)]. Adempas is indicated for the treatment of adults with pulmonary arterial hypertension (PAH), (WHO Group 1), to improve exercise capacity, WHO functional class and to delay clinical worsening. Efficacy was shown in patients on Adempas monotherapy or in combination with endothelin receptor antagonists or prostanoids. Studies establishing effectiveness included predominately patients with WHO functional class II–III and etiologies of idiopathic or heritable PAH (61%) or PAH associated with connective tissue diseases (25%) [see Clinical Studies (14.2)].
- generic_name
- riociguat
- product_names
- riociguat
- ndc
- 50419-250, 50419-250-01, 50419-250-03, 50419-250-91, 50419-250-71, 50419-251, 50419-251-01, 50419-251-03, 50419-251-91, 50419-251-71, 50419-252, 50419-252-01, 50419-252-03, 50419-252-91, 50419-253, 50419-253-01, 50419-253-03, 50419-253-91, 50419-254, 50419-254-01, 50419-254-03, 50419-254-91
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en